• Joanna Huang, Wasek Faisal, Margaret Brand, Shantelle Smith, Marliese Alexander, Lisa Briggs, Matthew Conron, Mary Duffy, Thomas John, David Langton, Jacqueline Lesage, Michael MacManus, Paul Mitchell, Inger Olesen, Phillip Parente, Jennifer Philip, Evangeline Samuel, Javier Torres, Craig R Underhill, John R Zalcberg, Susan Harden, and Rob Stirling.
• Alfred Health, Melbourne, VIC.
• Med. J. Aust. 2023 Aug 7; 219 (3): 120126120-126.

ObjectivesTo report stage-specific patterns of treatment and the influence of management and treatment type on survival rates for people newly diagnosed with small cell lung cancer (SCLC).DesignCross-sectional patterns of care study; analysis of data prospectively collected for the Victorian Lung Cancer Registry (VLCR).Setting, ParticipantsAll people diagnosed with SCLC in Victoria during 1 April 2011 - 18 December 2019.Main Outcome MeasuresStage-specific management and treatment of people with SCLC; median survival time.ResultsDuring 2011-19, 1006 people were diagnosed with SCLC (10.5% of all lung cancer diagnoses in Victoria); their median age was 69 years (interquartile range [IQR], 62-77 years), 429 were women (43%), and 921 were current or former smokers (92%). Clinical stage was defined for 896 people (89%; TNM stages I-III, 268 [30%]; TNM stage IV, 628 [70%]) and ECOG performance status at diagnosis for 663 (66%; 0 or 1, 489 [49%]; 2-4, 174 [17%]). The cases of 552 patients had been discussed at multidisciplinary meetings (55%), 377 people had received supportive care screening (37%), and 388 had been referred for palliative care (39%). Active treatment was received by 891 people (89%): chemotherapy, 843 (84%); radiotherapy, 460 (46%); chemotherapy and radiotherapy, 419 (42%); surgery, 23 (2%). Treatment had commenced within fourteen days of diagnosis for 632 of 875 patients (72%). Overall median survival time from diagnosis was 8.9 months (IQR, 4.2-16 months; stage I-III: 16.3 [IQR, 9.3-30] months; stage IV: 7.2 [IQR, 3.3-12] months). Multidisciplinary meeting presentation (hazard ratio [HR], 0.66; 95% CI, 0.58-0.77), multimodality treatment (HR, 0.42; 95% CI, 0.36-0.49), and chemotherapy within fourteen days of diagnosis (HR, 0.68; 95% CI, 0.48-0.94) were each associated with lower mortality during follow-up.ConclusionRates of supportive care screening, multidisciplinary meeting evaluation, and palliative care referral for people with SCLC could be improved. A national registry of SCLC-specific management and outcomes data could improve the quality and safety of care.© 2023 The Authors. Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd.

21 keywords...

hide…